Clara Bullich‐Vilarrubias

Clara Bullich‐Vilarrubias

Auto-generated profile, based on publicly available information

Clara Bullich‐Vilarrubias

Microbiome Innovation in Nutrition & Health Research Unit (INNOBIOME), Institute of Agrochemistry and Food Technology, Spanish National Research Council (IATA-CSIC)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MPMarina Romaní Pérez
Marina Romaní Pérez
ILInmaculada López‐Almela
Inmaculada López‐Almela
CBClara Bullich‐Vilarrubias
Clara Bullich‐Vilarrubias
LRLola Rueda Ruzafa
Lola Rueda Ruzafa
EPEva María Gómez del Pulgar
Eva María Gómez del Pulgar
YSYolanda Sanz
Yolanda Sanz
Impaired glucose homeostasis in obesity is mitigated by enhancing the glucoregulatory actions of glucagon‐like peptide 1 (GLP‐1), and thus, strategies that improve GLP‐1 sensitivity and secretion have therapeutic potential for the treatment of type 2 diabetes. This study shows that Holdemanella biformis , isolated from the feces of a metabolically healthy volunteer, ameliorates hyperglycemia, improves oral glucose tolerance and restores gluconeogenesis and insulin signaling in the liver of obese mice. These effects were associated with the ability of H . biformis to restore GLP‐1 levels, enhancing GLP‐1 neural signaling in the proximal and distal small intestine and GLP‐1 sensitivity of vagal sensory neurons, and to modify the cecal abundance of unsaturated fatty acids and the bacterial species associated with metabolic health. Our findings overall suggest the potential use of H biformis in the management of type 2 diabetes in obesity to optimize the sensitivity and function of the GLP‐1 system, through direct and indirect mechanisms.

1 December 2023 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
MPMarina Romaní Pérez
Marina Romaní Pérez
CBClara Bullich‐Vilarrubias
Clara Bullich‐Vilarrubias
ILInmaculada López‐Almela
Inmaculada López‐Almela
YSYolanda Sanz
Yolanda Sanz
Scope: Sensory neurons expressing the sodium channel Nav1.8 contain a repertoire of receptors for nutrient, hormonal, and inflammatory ligands. However, their function in key regulators of energy homeostasis control is not well understood and is completely unexplored in females.Methods and results: Mice lacking neurons expressing the sodium channel Nav1.8 were generated using an ablation strategy based on cre recombinase‐mediated expression of diphtheria toxin fragment A (DTA) (Nav1.8‐cre/DTA mice) to investigate whether these neurons modulate body weight, food intake, gut hormone secretion, gastrointestinal transit, and glucose tolerance in response to nutrient challenges in a sex‐dependent manner. Male Nav1.8‐cre/DTA mice show resistance to gain weight in response to high‐fat high‐sugar diet (HFHSD), whereas females lacking Nav1.8+ neurons have improved oral glucose tolerance accompanied by higher insulin levels and attenuated glucagon secretion after an oral glucose load. Female Nav1.8‐cre/DTA mice also show higher fasting and postprandial glucagon like peptide‐1 (GLP‐1) levels with an increased number of GLP‐1‐positive cells. Finally, ablation of Nav1.8‐expressing neurons accelerates the gastrointestinal transit in female mice under HFHSD.Conclusion: This data demonstrates sex‐dependent differences in the Nav1.8‐mediated regulation of energy metabolism, and provides new insights that may help in the design of sex‐specific neuromodulation therapies for metabolic disorders induced by diets rich in fats and simple sugars.

21 January 2026 in Gut Microbes
Verified
Journal Article
Open access
CBClara Bullich-Vilarrubias
Clara Bullich-Vilarrubias
MPMarina Romaní Pérez
Marina Romaní Pérez
ILInmaculada López-Almela
Inmaculada López-Almela
CPCarlos Pomares-Díaz
Carlos Pomares-Díaz
SFSilvia Basili Franzin
Silvia Basili Franzin
YSYolanda Sanz
Yolanda Sanz
Excess energy intake contributes to adiposity in obesity. We investigated whether the human intestinal bacterium Phascolarctobacterium faecium could prevent obesity via enteroendocrine pathways in a mouse model of diet-induced obesity (DIO). Daily administration of P. faecium (2 × 109 cells/mouse) reduced food intake through the early overproduction of the satiety hormone peptide YY (PYY) compared to untreated DIO mice. Moreover, P. faecium increased the intestinal levels of branched-chain amino acids, which, in turn, stimulated PYY secretion in neuroendocrine cell cultures and also modified gut microbiota composition. A pair-feeding study demonstrated that the anorexigenic effect of P. faecium contributes to its effects in attenuating body weight gain in DIO mice, but that other mechanisms are also involved in its metabolic benefits. Specifically, P. faecium accelerated gut transit and serum lipid clearance, thereby limiting adiposity independently of food intake. This study identifies the mode of action of a human intestinal bacterium recently linked to obesity protection, providing valuable insights into host-microbe interactions governing body weight.